Table 1.

Summary of patient data.

	Patient ID	Dose level (µg/Kg)	Primary cancer	HA staining2	Response3	Lesions on DW-MRI	Lesions on T1w-MRI	Lesions on DCE-MRI
HALO-109-101	101–001-109	0.75	Ovarian	–	SD	1	0	0
	101–002-102	50	CRC	–	PD	1	0	0
	101–002-106	0.5	CRC	–	PD	1	0	0
	101–002-114	1.5	Prostate	–	PD	1	0	0
	101–003-103	0.5	CRC	–	AE	8	0	0
	101–003-104	0.5	Pancreas	10%,0,150 → –	PD	1	0	0
	101–003-105	0.5	Bladder	–	PD	3	0	0
	101–003-108	0.75	Carcinoid	–	PD	5	0	0
	101–003-110	0.75	CRC	–	PD	1	0	0
	102–003-112	1	NSCLC	–	PD	1	0	0
HALO-109-102	102–002-102	1.6	Esophageal	–	PD	1	0	1
	102–002-103	5	NSCLC	–	AE	0	1	1
	102–002-113	3	Pancreas	–	AE	1	1	1
	102–002-115	3	Pancreas	–	AE	1	1	1
	102–002-126	3	CRC	–	SD	1	1	1
	102–003-104	1.6	CRC	T2: 17.9%,–,– → 3.5%,–,–	PD	2	2	2
	102–003-105	1.6	CRC	-	PD	5	2	2
	102–003-117	3	CRC	12.2%,–,– → 20.8%,–,–	PD	1	1	1
	102–003-118	3	Tonsil	–	PD	1	1	1
	102–005-111	3	CRC	–	AE	1	1	1
	102–006-107	3	Pancreas	–	PD	1	1	1
	102–006-110	3	CRC	–	AE	1	1	1
	102–006-124	3	CRC	–	PD	1	1	1
HALO-109-201	201–001-301	3	Pancreas	–,280,270 → –		PR	0	1
	201–001-304	3	Pancreas	–	PR	0	1	1
	201–003-306	3	Pancreas	–	SD	0	1	1
	201–007-405	3	Pancreas	T1: –,40,260 → –,15,150	PR	0	3	5
	201–007-409	3	Pancreas	–,100,240 → –	PR	0	1	1
	201–007-414	3	Pancreas	T1: –,30,190 → –	PR	0	5	5
	# Patients: 29				# Lesions:	40	26	29

¹CRC: Colorectal Cancer, NSCLC: Non-small-cell lung carcinoma.

²Tumor biopsied (in case of multiple tumors): HA%, tumor, and stroma H-score before and after PEGPH20.

³Response by RECIST. SD: Stable Disease, PD: Progressive Disease, PR: Partial Response, AE: discontinuation of the study due to Adverse Events.